Skip to main content
Erschienen in: The European Journal of Health Economics 1/2017

07.01.2016 | Original Paper

Cost-of-illness analysis and regression modeling in cystic fibrosis: a retrospective prevalence-based study

verfasst von: Tomáš Mlčoch, Jiří Klimeš, Libor Fila, Věra Vávrová, Veronika Skalická, Marek Turnovec, Veronika Krulišová, Jitka Jirčíková, Dana Zemková, Klára Vilimovská Dědečková, Alena Bílková, Vladimíra Frühaufová, Lukáš Homola, Zuzana Friedmannová, Radovan Drnek, Pavel Dřevínek, Tomáš Doležal, Milan Macek Jr.

Erschienen in: The European Journal of Health Economics | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Economic data pertaining to cystic fibrosis (CF), is limited in Europe generally, and completely lacking in Central and Eastern Europe. We performed an analysis of all direct costs associated with CF relative to key disease features and laboratory examinations.

Methods

A retrospective prevalence-based cost-of-illness (COI) study was performed in a representative cohort of 242 CF patients in the Czech Republic, which represents about 65 % of all Czech CF patients. Medical records and invoices to health insurance companies for reference year 2010 were analyzed.

Results

The mean total health care costs were €14,486 per patient, with the majority of the costs going towards medicinal products and devices (€10,321). Medical procedures (€2676) and inpatient care (€1829) represented a much smaller percentage of costs. A generalized linear model showed that the strongest cost drivers, for all cost categories, were associated with patient age and lung disease severity (assessed using the FEV1 spirometric parameter), when compounded by chronic Pseudomonas aeruginosa airway infections. Specifically, maximum total costs are around the age 16 years; a FEV1 increase of 1 % point represented a cost decrease of: 0.9 % (medicinal products), 1.7 % (total costs), 2.8 % (procedures) and 7.0 % (inpatient care).

Conclusions

COI analysis and regression modeling using the most recent data available can provide a better understanding of the overall economic CF burden. A comparison of our results with other methodologically similar studies demonstrates that although overall costs may differ, FEV1 can nonetheless be utilized as a generally transferrable indicator of the relative economic impact of CF.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
3.
Zurück zum Zitat Klimeš, J., Doležal, T., Kubáčková, K., Turnovec, M., Macek Jr., M.: Health-economic aspects of cystic fibrosis screening and therapy. Eur. Respir. Soc. monogr. 64, 304–319 (2014) Klimeš, J., Doležal, T., Kubáčková, K., Turnovec, M., Macek Jr., M.: Health-economic aspects of cystic fibrosis screening and therapy. Eur. Respir. Soc. monogr. 64, 304–319 (2014)
12.
Zurück zum Zitat Balascakova, M., Holubova, A., Skalicka, V., Zemkova, D., Kracmar, P., Gonsorcikova, L., Camajova, J., Piskackova, T., Lebl, J., Drevinek, P., et al.: Pilot newborn screening project for cystic fibrosis in the Czech Republic: defining role of the delay in its symptomatic diagnosis and influence of ultrasound-based prenatal diagnosis on the incidence of the disease. J. Cyst. Fibros. 8, 224–227 (2009). http://www.cysticfibrosisjournal.com/article/S1569-1993(09)00004-6/abstract Balascakova, M., Holubova, A., Skalicka, V., Zemkova, D., Kracmar, P., Gonsorcikova, L., Camajova, J., Piskackova, T., Lebl, J., Drevinek, P., et al.: Pilot newborn screening project for cystic fibrosis in the Czech Republic: defining role of the delay in its symptomatic diagnosis and influence of ultrasound-based prenatal diagnosis on the incidence of the disease. J. Cyst. Fibros. 8, 224–227 (2009). http://​www.​cysticfibrosisjo​urnal.​com/​article/​S1569-1993(09)00004-6/​abstract
20.
Zurück zum Zitat Křenková, P., Piskáčková, T., Holubová, A., Balascakova, M., Krulisova, V., Camajova, J., Turnovec, M., Libik, M., Norambuena, P., Stambergova, A., et al.: Distribution of CFTR mutations in the Czech population: positive impact of integrated clinical and laboratory expertise, detection of novel/de novo alleles and relevance for related/derived populations. J. Cyst. Fibros. 12, 532–537 (2013). http://linkinghub.elsevier.com/retrieve/pii/S1569-1993(12)00235-4 Křenková, P., Piskáčková, T., Holubová, A., Balascakova, M., Krulisova, V., Camajova, J., Turnovec, M., Libik, M., Norambuena, P., Stambergova, A., et al.: Distribution of CFTR mutations in the Czech population: positive impact of integrated clinical and laboratory expertise, detection of novel/de novo alleles and relevance for related/derived populations. J. Cyst. Fibros. 12, 532–537 (2013). http://​linkinghub.​elsevier.​com/​retrieve/​pii/​S1569-1993(12)00235-4
Metadaten
Titel
Cost-of-illness analysis and regression modeling in cystic fibrosis: a retrospective prevalence-based study
verfasst von
Tomáš Mlčoch
Jiří Klimeš
Libor Fila
Věra Vávrová
Veronika Skalická
Marek Turnovec
Veronika Krulišová
Jitka Jirčíková
Dana Zemková
Klára Vilimovská Dědečková
Alena Bílková
Vladimíra Frühaufová
Lukáš Homola
Zuzana Friedmannová
Radovan Drnek
Pavel Dřevínek
Tomáš Doležal
Milan Macek Jr.
Publikationsdatum
07.01.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
The European Journal of Health Economics / Ausgabe 1/2017
Print ISSN: 1618-7598
Elektronische ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-015-0759-9

Weitere Artikel der Ausgabe 1/2017

The European Journal of Health Economics 1/2017 Zur Ausgabe